Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.

De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A.

Int J Geriatr Psychiatry. 2004 Feb;19(2):115-26.

PMID:
14758577
2.

[Prescription of olanzapine in children and adolescent psychiatric patients].

Frémaux T, Reymann JM, Chevreuil C, Bentué-Ferrer D.

Encephale. 2007 Mar-Apr;33(2):188-96. Review. French.

PMID:
17675914
3.

The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.

Ballard C, Waite J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003476. Review.

PMID:
16437455
4.

Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.

Schatz RA.

Ann Pharmacother. 2003 Sep;37(9):1321-4. Review.

PMID:
12921516
5.

Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.

Bozymski KM, Lowe DK, Pasternak KM, Gatesman TL, Crouse EL.

Ann Pharmacother. 2017 Jun;51(6):479-487. doi: 10.1177/1060028017693029. Epub 2017 Feb 1. Review.

PMID:
28375643
6.

[Treatment of non cognitive symptoms of Alzheimer's disease].

Grau-Veciana JM.

Rev Neurol. 2006 Apr 16-30;42(8):482-8. Review. Spanish.

7.

The management of other psychiatric states. Hallucinations, delusions, and other disturbances.

Loebel JP, Leibovici A.

Med Clin North Am. 1994 Jul;78(4):841-59. Review.

PMID:
8022232
8.

Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.

Sahli ZT, Tarazi FI.

Expert Opin Drug Discov. 2018 Jan;13(1):103-110. doi: 10.1080/17460441.2018.1394838. Epub 2017 Oct 31. Review.

PMID:
29047301
9.

Neuroleptic treatment of agitation and psychosis in dementia.

Devanand DP, Levy SR.

J Geriatr Psychiatry Neurol. 1995 Oct;8 Suppl 1:S18-27. Review.

PMID:
8561840
10.

The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.

Mathis MV, Muoio BM, Andreason P, Avila AM, Farchione T, Atrakchi A, Temple RJ.

J Clin Psychiatry. 2017 Jun;78(6):e668-e673. doi: 10.4088/JCP.16r11119. Review.

PMID:
28493654
11.

Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.

Kianirad Y, Simuni T.

Expert Rev Clin Pharmacol. 2017 Nov;10(11):1161-1168. doi: 10.1080/17512433.2017.1369405. Epub 2017 Oct 17. Review.

PMID:
28817967
12.

Psychosis secondary to traumatic brain injury.

Guerreiro DF, Navarro R, Silva M, Carvalho M, Gois C.

Brain Inj. 2009 Apr;23(4):358-61. doi: 10.1080/02699050902800918. Review.

PMID:
19274520
13.

[Diagnosis of psychological and behavioural disorders in Alzheimer's disease].

Pancrazi MP, Metais P.

Presse Med. 2005 May 14;34(9):661-6, 660. Review. French.

PMID:
15988345
14.

Drugs with anticholinergic properties: a potential risk factor for psychosis onset in Alzheimer's disease?

Cancelli I, Beltrame M, D'Anna L, Gigli GL, Valente M.

Expert Opin Drug Saf. 2009 Sep;8(5):549-57. doi: 10.1517/14740330903099636. Review.

PMID:
19552610
15.

Psychosis in Alzheimer's disease.

Murray PS, Kumar S, Demichele-Sweet MA, Sweet RA.

Biol Psychiatry. 2014 Apr 1;75(7):542-52. doi: 10.1016/j.biopsych.2013.08.020. Epub 2013 Oct 6. Review.

Supplemental Content

Support Center